(Q38298229)

English

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study

scientific article published on 23 December 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

multicenter clinical trial

0 references

oligodendroglioma

1 reference

based on heuristic

inferred from title

anaplastic oligodendroglioma

1 reference

based on heuristic

inferred from title

adult oligodendroglioma

1 reference

based on heuristic

inferred from title

6

object named as

Paul G Fisher

0 references

author name string

Manmeet S Ahluwalia

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Hao Xie

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Saurabh Dahiya

3

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Nooshin Hashemi-Sadraei

4

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

David Schiff

5

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Paul G Fisher

6

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Marc C Chamberlain

7

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Susan Pannullo

8

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Herbert B Newton

9

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Cathy Brewer

10

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Laura Wood

11

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Richard Prayson

12

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Paul Elson

13

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

David M Peereboom

14

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

23 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

122

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

111-119

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Impact of brain tumour treatment on quality of life

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1684-Y

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25534576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25534576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25534576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://pubmed.ncbi.nlm.nih.gov/25534576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25534576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-014-1684-Y

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38298229&oldid=2201533226"